209 related articles for article (PubMed ID: 34366836)
1. Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan.
Li KJ; Chang CL; Hsin CY; Tang CH
Front Pharmacol; 2021; 12():628548. PubMed ID: 34366836
[TBL] [Abstract][Full Text] [Related]
2. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
3. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
6. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
8. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
[TBL] [Abstract][Full Text] [Related]
10. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
11. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
12. Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
Best JH; Vlad SC; Tominna L; Abbass I
Rheumatol Ther; 2020 Jun; 7(2):345-355. PubMed ID: 32227284
[TBL] [Abstract][Full Text] [Related]
13. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
14. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
[TBL] [Abstract][Full Text] [Related]
16. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
17. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study.
Fisher A; Hudson M; Platt RW; Dormuth CR;
J Rheumatol; 2021 Jan; 48(1):16-24. PubMed ID: 33004534
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea.
Park JA; Lee MY; Nam JH; Shin JY; Wood R; Holbrook T; Kwon SH
Curr Med Res Opin; 2020 Feb; 36(2):343-351. PubMed ID: 31670976
[No Abstract] [Full Text] [Related]
[Next] [New Search]